| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | RG-108 | CTRPv2 | pan-cancer | AAC | -0.097 | 0.008 |
| mRNA | Crizotinib | CTRPv2 | pan-cancer | AAC | -0.086 | 0.008 |
| mRNA | decitabine:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.084 | 0.008 |
| mRNA | BRD-K13999467 | CTRPv2 | pan-cancer | AAC | -0.094 | 0.009 |
| mRNA | oligomycin a | CTRPv2 | pan-cancer | AAC | -0.092 | 0.01 |
| mRNA | GSK4112 | CTRPv2 | pan-cancer | AAC | 0.094 | 0.01 |
| mRNA | KW-2449 | CTRPv2 | pan-cancer | AAC | -0.077 | 0.01 |
| mRNA | BI-2536 | CTRPv2 | pan-cancer | AAC | -0.08 | 0.01 |
| mRNA | Imatinib | CTRPv2 | pan-cancer | AAC | -0.09 | 0.01 |
| mRNA | dabrafenib | CTRPv2 | pan-cancer | AAC | -0.12 | 0.01 |